Touchlight’s facility in Hampton, UK has received GMP certification, making the CDMO the first synthetic DNA manufacturer globally to gain regulatory approval to produce Active Pharmaceutical Ingredients (APIs). Specifically, Touchlight has received a Manufacturer’s Authorization for Investigational Medicinal Products (MIA, IMP) license from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the GMP (Good Manufacturing Practices) production of Investigational API and Crit...